JJ
RLYB icon

Johnson & Johnson’s Rallybio RLYB Stock Holding History

Johnson & Johnson’s Portfolio RLYB Stock Details RLYB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-152,901
Closed -$1.37M – 17
2026
Q1 		$1.37M Sell
152,901
-301,644
-66% -$2.06M 0.21% 12
2025
Q4 		$2.49M Hold
454,545
– – 0.45% 12
2025
Q3 		$1.81M Hold
454,545
– – 0.36% 14
2025
Q2 		$1.21M Hold
454,545
– – 0.36% 13
2025
Q1 		$2.38M Hold
454,545
– – 0.7% 12
2024
Q4 		$3.49M Hold
454,545
– – 0.9% 13
2024
Q3 		$4.25M Hold
454,545
– – 1% 13
2024
Q2 		$4.87M Buy
+454,545
New +$6.16M 1.22% 13

Other funds holding RLYB

ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return

Johnson & Johnson's RLYB Position: Q2 2026 in Review

Johnson & Johnson sold out of Rallybio (RLYB) in Q2 2026, closing a stake of 152,901 shares — an estimated $1.37M sold.

Johnson & Johnson first reported a position in RLYB in Q2 2024 and held it in 8 quarters. The position peaked at $4.87M in Q2 2024. 37 funds tracked by Wall St. Rank hold RLYB as of Q2 2026.

  • Johnson & Johnson reported no remaining Rallybio position as of Q2 2026 after selling out during the quarter.
  • Johnson & Johnson sold 152,901 Rallybio shares in Q2 2026, an estimated $1.37M.
  • Johnson & Johnson first reported a position in Rallybio in Q2 2024 and held it in 8 quarters.
  • Johnson & Johnson's Rallybio position peaked at $4.87M in Q2 2024.
  • 37 funds tracked by Wall St. Rank held Rallybio as of Q2 2026.

Based on Johnson & Johnson's 13F filing for Q2 2026, filed 6 Aug 2026.